Last reviewed · How we verify
NCT05557903
Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL
Phase 1 trial testing Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection in Lymphoma, Non-Hodgkin in 71 participants. Status unknown.
30 December 2022
Quick facts
| Lead sponsor | Lanzhou Institute of Biological Products Co., Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 71 |
| Start date | 20 December 2021 |
| Primary completion | 30 December 2022 |
| Estimated completion | 30 June 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection — full drug profile →
Conditions studied
- Lymphoma, Non-Hodgkin — all drugs for Lymphoma, Non-Hodgkin →
- Lymphoma, T-Cell — all drugs for Lymphoma, T-Cell →
Sponsor
Lanzhou Institute of Biological Products Co., Ltd — full company profile →
Who can join
Adults 18 to 70, any sex, with Lymphoma, Non-Hodgkin or Lymphoma, T-Cell. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Phase I clinical study of multicenter, single-arm, open, non-randomized evaluation of recombinant humanized anti-CD52 monoclonal antibody in the NHL and T-PLL
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05557903
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lymphoma, Non-Hodgkin
Currently open trials in the same condition.
- NCT07308132 — A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies · Phase 1 · recruiting
- NCT06923397 — Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemother · NA · recruiting
- NCT06660563 — A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell No · Phase 1 · active not recruiting
- NCT06343311 — T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) · Phase 1, PHASE2 · recruiting
- NCT06470438 — A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma · Phase 1 · active not recruiting
Other Lanzhou Institute of Biological Products Co., Ltd trials
Trials by the same sponsor.
- NCT07445815 — A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody · Phase 2 · not yet recruiting
- NCT07149454 — Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Te · Phase 1 · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05557903 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lanzhou Institute of Biological Products Co., Ltd
- Last refreshed: 28 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05557903.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing